All In Biotech

Drug Trial Radar · NCT07304843

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

A Randomised, Double-blind, Placebo-controlled, Two-part Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Preliminary Efficacy of Two Dose Levels of Golexanolone in Subjects With Primary Biliary Cholangitis (PBC), Fatigue, and Cognitive Dysfunction

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Apr 14, 2023

Primary completion

Sep 9, 2026

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Umecrine Cognition ABIndustry
Sponsor type
Industry
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone compared with placebo among subjects with a history of non-cirrhotic or Child-Pugh class A cirrhotic Primary Biliary Cholangitis (PBC) with clinically significant fatigue and cognitive symptoms on stable background standard of care (SoC) PBC medication. The objectives of this research study are to assess the safety and tolerability as well the pharmacokinetic (PK) characteristics of golexanolone administered 40 mg BID for 5 days in the target population (part A) and to assess the safety and tolerability, the effects of golexanolone on health-related quality of life (HRQoL), including fatigue, day-time sleepiness and cognitive function as well as Investigator's overall impression of treatment effect of 28 days twice per day (BID) treatment with two dose levels of golexanolone versus placebo (part B).

Conditions

  • Primary Biliary Cholangitis (PBC)

Interventions

  • golexanoloneDrug

    soft gelatin capsules, oral dosage twice per day for up to 28 days

  • golexanoloneDrug

    soft gelatin capsules, oral dosage twice a day for up to 28 days

  • PlaceboDrug

    soft gelatin capsules, oral dosage twice a day for up to 28 days

  • golexanoloneDrug

    soft gelatin capsules, oral dosage twice per day for 5 days

  • PlaceboDrug

    soft gelatin capsules, oral dosage twice per day for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 28 (part B)Time frame: From enrollment to the end of treatment at 28 days
  2. Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 5 (part A)Time frame: From Baseline to Day 5

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • University Hospital Düsseldorf

    Düsseldorf, Germany

  • University of Leipzig

    Leipzig, Germany

  • Hippokration General Hospital of Athens

    Athens, Greece

  • University Hospital of Patras

    Pátrai, Greece

  • Facility of CRU Hungary Ltd.

    Kistarcsa, Hungary

  • Università di Milano-Bicocca, S.C. ASST Grande Ospedale Metropolitano Niguarda, Dipartimento di Medicina e Chirurgia, Epatologia e Gastroenterologia

    Milan, Italy

  • University of Padova, Department of Surgery, Oncology and Gastroenterology

    Padova, Italy

  • University Hospital Paolo Giaccone, University of Palermo

    Palermo, Italy

  • A. Gemelli Polyclinic, Sacro Cuore Catholic University

    Roma, Italy

  • Humanitas University

    Rozzano, Italy

  • University of Udine

    Udine, Italy

  • University Medical Center "Zvezdara"

    Belgrade, Serbia

  • Hospital Universitario Parc Taulí

    Barcelona, Spain

  • Hospital Clinic Barcelona

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital 12th October, Madrid

    Madrid, Spain

  • Hospital Universitario Virgen De La Victoria

    Málaga, Spain

  • University Hospital Complex of Pontevedra & IIS Galicia South, Pontevedra

    Pontevedra, Spain

  • University Hospital Marquez de Valdecilla, Santander

    Santander, Spain

  • Virgen del Rocio University Hospital

    Seville, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Hacettepe University, Fakulty of Medicine, Department of Gastroenterology and Hepatology

    Ankara, Turkey (Türkiye)

  • 9 Eylul University Research and Application Hospital Department of Gastroenterology

    Balçova, Turkey (Türkiye)

  • Dicle University Faculty of Medicine Department of Gastroenterology

    Diyarbakır, Turkey (Türkiye)

  • Ege University Faculty of Medicine, Department of Gastroenterology

    Izmir, Turkey (Türkiye)

  • Kocaeli University Faculty of Medicine Gastroenterology and Hepatology Department

    Kocaeli, Turkey (Türkiye)

  • Recep Tayyip Erdoğan University Training and Research Hospital, Department of Gastroenterology

    Rize, Turkey (Türkiye)

  • Harran Üniversitesi Osmanbey Campus Department of Gastroenterology

    Sanliurfa, Turkey (Türkiye)

  • Karadeniz Technical University, Farabi Hospital, Department of Gastroenterology

    Trabzon, Turkey (Türkiye)

  • NIHR Birmingham BRC

    Birmingham, United Kingdom

  • Glasgow Royal Infirmary

    Glasgow, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • Guy's and St Thomas' Hospital, London

    London, United Kingdom

  • Freeman Hospital

    Newcastle, United Kingdom

  • Nottingham Digestive Diseases Centre and Biomedical Research Centre Nottingham University Hospitals NHS Trust, Queen's Medical Centre

    Nottingham, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

  • Dept of Gastroenterology & Hepatology Portsmouth Hospitals University NHS Trust Queen Alexandra Hospital

    Portsmouth, United Kingdom

  • Royal Wolverhampton NHS Trust, New Cross Hospital

    Wolverhampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.